Society guidelines (1) recommend cardiac resynchronization therapy (CRT) to patients with symptomatic heart failure (HF) New York Heart Association (NYHA) class III and IV in patients with wide QRS (Ͼ120 ms) and systolic left ventricular (LV) dysfunction (LV ejection fraction [LVEF] of Ͻ35%). Its benefits are well known, including LV remodeling, decrease in HF symptoms and hospitalizations, and decreased mortality.
Current American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines (1) recommend cardiac resynchronization therapy (CRT) to patients with symptomatic heart failure (HF) New York Heart Association (NYHA) class III and IV in patients with wide QRS (Ͼ120 ms) and systolic left ventricular (LV) dysfunction (LV ejection fraction [LVEF] of Ͻ35%). Its benefits are well known, including LV remodeling, decrease in HF symptoms and hospitalizations, and decreased mortality. Most recently, the REVERSE (Resynchronization Reverses Remodeling in Systolic LV Dysfunction) (2) and MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trail With Cardiac Resynchronization Therapy) (3) trials demonstrated additional benefits of CRT in NYHA class I to II.
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Unfortunately, the degree of response to CRT varies among patients. Right bundle branch block, ischemic cardiomyopathy (CM), NYHA class IV HF, chronic renal failure, diabetes mellitus, increased levels of brain natriuretic peptide, severe mitral regurgitation, and advanced age have been associated with poorer outcomes after CRT with defibrillator implantation (4 -7). In contrast, CRT responders and super-or hyperresponders (based on improvement of LVEF and LV dimensions) have been found to have an improved outcome and survival benefit (8 -10) . Unfortunately, clinical studies to identify predictors of CRT response and super-response in symptomatic class II to IV HF have shown variable results (Tables 1 and 2 ). The discrepancy between different studies can best be explained by the wide range of criteria (up to 17 criteria) to define CRT response and super-or hyper-response (11) . In this issue of the Journal, Hsu et al. (12) reported the predictors that may forecast CRT super-response in NYHA class I to II HF from the MADIT-CRT trial. The present study is welcome-it is the largest and most carefully analyzed patient cohort providing invaluable information to clinicians about CRT response. Predictors of CRT response. Most prior studies have found that nonischemic CM (NICM), left bundle branch block (LBBB), baseline wider QRS, and smaller LV dimensions seem to predict CRT response; however, some predictors may not translate into improved survival (10, 13) . Female sex has been noted to be a potential predictor of CRT response; however, the prevalence of NICM and LBBB appears to be higher in women than men (10) . In addition, echocardiographic parameters of dyssynchrony have failed to predict CRT response when studied in the PROSPECT (Predictors of Response to CRT) trial (14) , mainly attributed to a high interobserver and intraobserver variability of these parameters. Recently, Goldenberg et al. (15) reported 7 predictors of echocardiographic CRT response (defined as percent reduction in LV end-diastolic volume after 1 year of CRT) in the MADIT-CRT trial (NYHA class I to II), which included female sex, nonischemic origin, LBBB, QRS Ͼ150 ms, prior hospitalization for HF, LV enddiastolic volume Ͼ125 ml/m 2 , and left atrial volume Ͻ40 ml/m 2 (15) . They proposed a 0-to 14-point response score based on these 7 factors, with a risk reduction of HF or death with CRT of 69%, 36%, and 33% for the upper (Ͼ9 points), third, and second quartiles, respectively; without significant risk reduction in the first quartile (Ͻ4 points).
Predictors of super-or hyper-response to CRT.
Prior clinical studies in patients with symptomatic HF have reported an incidence of 10% to 29% of CRT "hyper-" or "super-"responders (commonly defined as LVEF Ͼ50% and functional recovery NYHA class I or II) after 6 months of CRT. Serdoz et al. (16) reported that NICM, baseline QRS Ͼ150 ms, and QRS shortening Ͼ40 ms during CRT had a 75% probability of restoration of normal LVEF in NYHA class III to IV. Most predictors of super-or hyperresponders (Table 2) are not different than those predictors of overall CRT response (Table 1) . Only duration of HF symptoms and CM diagnosis has been reported to identify hyper-responders (9, 17) .
In this issue of the Journal, Hsu et al. (12) reported for the first time the predictors of CRT super-responders (highest quartile of LVEF change after CRT implant) in asymptomatic NYHA class I to II HF after 6 months of CRT, which included female sex, lack of prior myocardial infarction, QRS duration Ͼ150 ms, LBBB, body mass index Ͻ30 kg/m 2 , and smaller left atrial volume index. Most of these predictors are similar to those reported to predict overall CRT response in the same MADIT-CRT population (NYHA class I and II) (15) , except for body mass index and left atrial volume index. A lower incidence of primary (HF admission and all-cause death) and secondary (all-cause death or implantable cardioverter defibrillator therapy) endpoints was found in the superresponders group, and these predictors may stratify for better outcomes and survival (3) . The time frame of super-or hyper-response to CRT has been variable among patients in prior reports (usually between 3 and 6 months), but complete LVEF recovery has been noted even after 24 months (18, 19) . Thus, a single 12-month follow-up does not allow assessment of the time course of recovery of LV function.
Obviously, a better understanding of predictors of nonresponders, responders, and super-responders (complete resolution of LV dysfunction and HF symptoms) after CRT is needed to achieve better outcomes and decrease unnecessary procedures and expenses related to this therapy. However, the definition of all of these terms should be further standardized. In the final analysis, the present study provided confirmation of the concept of an electrical reversible cardiomyopathy and helps clinicians identify features that predict which patients may expect to demonstrate remarkable improvements from CRT. ⌬QRS ϭ difference between CRT and pre-implant QRS width; 6MWH ϭ 6-min hall walk; ACE ϭ angiotensin-converting enzyme; CCS ϭ clinical composite score (13) (all-cause mortality, NYHA functional class, HF admission, and patient global assessment); CRT ϭ cardiac resynchronization therapy; EF ϭ ejection fraction; HF ϭ heart failure; ICM ϭ ischemic cardiomyopathy; LAV ϭ left atrial volume; LBBB ϭ left bundle branch block; LV ϭ left ventricular; LVEDD ϭ LV end-diastolic diameter; LVEDV ϭ LV end-diastolic volume; LVEF ϭ LV ejection fraction; LVESD ϭ LV end-systolic diameter; LVESV ϭ LV end-systolic volume; MD, mechanical dyssynchrony; NICM ϭ nonischemic cardiomyopathy; NS ϭ not specified; NYHA ϭ New York Heart Association; OR ϭ odds ratio; S-L delay ϭ septal to lateral delay; TR ϭ tricuspid regurgitation. 
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